Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangmin Li

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Bioconjugate Chemistry|September 9, 2017
Attachment Site Cysteine Thiol pK<sub>a</sub> Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug ConjugatesBreanna S Vollmar, Binqing Wei, Rachana Ohri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapyGail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Journal of the American Chemical Society|July 1, 2024
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to TherapyPragya Adhikari, Guangmin Li, MaryAnn Go, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Cancer Research|September 18, 2014
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.
Journal of Medicinal Chemistry|August 14, 2020
Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug ConjugatesLeanna R Staben, Jinhua Chen, Josefa Dela Cruz-Chuh, et al.
Journal of Medicinal Chemistry|November 8, 2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-LinkersStephen J Gregson, Luke A Masterson, Binqing Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Bioconjugate Chemistry|June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug ConjugatesJack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Bioconjugate Chemistry|September 9, 2017
Attachment Site Cysteine Thiol pK<sub>a</sub> Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug ConjugatesBreanna S Vollmar, Binqing Wei, Rachana Ohri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapyGail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Journal of the American Chemical Society|July 1, 2024
On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to TherapyPragya Adhikari, Guangmin Li, MaryAnn Go, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancerJagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Cancer Research|November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateGail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Cancer Research|September 18, 2014
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.
Journal of Medicinal Chemistry|August 14, 2020
Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug ConjugatesLeanna R Staben, Jinhua Chen, Josefa Dela Cruz-Chuh, et al.
Journal of Medicinal Chemistry|November 8, 2017
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-LinkersStephen J Gregson, Luke A Masterson, Binqing Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipDirk B Mendel, A Douglas Laird, Xiaohua Xin, et al.
Bioconjugate Chemistry|June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug ConjugatesJack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.
Pageof 4